Sunday, July 16, 2006

Merck - Vioxx: the way ahead

This thought provoking piece looks at Merck's "case by case" strategy and how it might pan out.

Whilst still somewhat irked by the recent NJ win for Merck, Insider has calmed down and actually can see an upside.

He doesnt want Merck to go under completely.

That would benefit no one.

Just a deep deep wounding would be fine. That might lead to healing, change and, hopefully, rehabilitation.

Insider's best guess: 23,000 cases costing Merck $28 billion.

No comments: